Prevention & lipidsMeta-analysis

Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials

Eur Heart JPublished

  • Pooled analysis of randomised trials
  • placebo-controlled

Authors' conclusion

Obicetrapib lowered LDL-C, apoB and Lp(a). The absolute reduction in Lp(a) with obicetrapib was similar in patients with mildly elevated Lp(a) levels, who are unlikely to qualify for administration of RNA-targeted Lp(a) lowering agents.

Study context

Population
Patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) at high CV risk
Participants
2,356 patients
Comparison
Obicetrapib 10 mg daily vs placebo
Outcome
Change in Lp(a) levels
Follow-up
12 weeks

Pooled result

As reported in the abstract

Lp(a), placebo-adjusted reduction
Obicetrapib
placebo-adjusted reduction 37.3 %
Obicetrapib
placebo-adjusted reduction 14.9 nmol/L

Further pooled results

OutcomeEstimate
LDL-C, placebo-adjusted reduction — Obicetrapib vs Placeboplacebo-adjusted reduction 37.0 %
LDL-C, placebo-adjusted reduction — Obicetrapib vs Placeboplacebo-adjusted reduction 35 mg/dL
apoB, placebo-adjusted reduction — Obicetrapib vs Placeboplacebo-adjusted reduction 21.3 %
apoB, placebo-adjusted reduction — Obicetrapib vs Placeboplacebo-adjusted reduction 20 mg/dL
Lp(a), baseline Lp(a) ≥50-<150 nmol/L (subgroup) — Obicetrapib vs Placeboplacebo-adjusted reduction 43.3 %
Lp(a), baseline Lp(a) ≥50-<150 nmol/L (subgroup) — Obicetrapib vs Placeboplacebo-adjusted reduction 36.3 nmol/L

Lp(a), baseline Lp(a) ≥150 nmol/L vs ≥50-<150 nmol/L (subgroups)

Lower percentage reduction with baseline ≥150 nmol/L; absolute reduction similar in both
−32.3 vs −36.3 nmol/L

Original publication

Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. Eur Heart J. Published 25 May 2026. doi:10.1093/eurheartj/ehag399

Summarised from the published abstract; every number is checked against it